Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Return on Equity (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Return on Equity for 5 consecutive years, with 0.12% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 4.0% to 0.12% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.12%, a 4.0% decrease, with the full-year FY2025 number at 0.11%, down 1.0% from a year prior.
  • Return on Equity was 0.12% for Q4 2025 at Janux Therapeutics, down from 0.1% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.3% in Q1 2021 to a low of 0.22% in Q2 2023.
  • A 5-year average of 0.1% and a median of 0.11% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: crashed -42bps in 2022, then rose 15bps in 2024.
  • Janux Therapeutics' Return on Equity stood at 0.09% in 2021, then crashed by -120bps to 0.19% in 2022, then rose by 13bps to 0.17% in 2023, then skyrocketed by 51bps to 0.08% in 2024, then tumbled by -43bps to 0.12% in 2025.
  • Per Business Quant, the three most recent readings for JANX's Return on Equity are 0.12% (Q4 2025), 0.1% (Q3 2025), and 0.11% (Q2 2025).